ECTE Financial Facts

Interest expense: -133.06K
Research and development: 588.55K
See Full Income Statement

Preferred stock: 10K
Total current liabilities: 7.27M
See Full Balance Sheet

Echo Therapeutics (ECTE) Earnings

  |   Expand Research on ECTE
Next EPS Date N/A EPS Growth Rate +15.5% *Last Qtr.
Average EPS % Beat Rate +9.5% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -14.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/12/16 Q216 -$0.82N/A N/A N/AN/A N/A Details
5/20/16 Q116 -$0.23N/A N/A N/AN/A N/A Details
11/16/15 Q315 -$0.16N/A N/A N/AN/A N/A Details
8/14/15 Q215 -$0.97N/A N/A N/AN/A N/A Details
11/19/14 Q314 -$0.43N/A N/A $19.11M$22.56M N/A Details
8/14/14 Q214 -$0.31-$0.23 -$0.08$19.1M$22.56M N/A Details
5/9/14 Q114 -$0.23-$0.31 +$0.08$19.11K$20K N/A Details
3/27/14 Q413 -$0.36-$0.40 +$0.04N/A$20K N/A Details